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Dilated cardiomyopathyPhospholamban (PLN) is a single-passmembrane protein that regulates the sarco(endo)plasmic reticulumCa2+-
ATPase (SERCA). Phosphorylation of PLN at Ser16 reverses its inhibitory function underβ-adrenergic stimulation,
augmenting Ca2+ uptake in the sarcoplasmic reticulum and muscle contractility. PLN exists in two conforma-
tions; a T state, where the cytoplasmic domain is helical and adsorbed on the membrane surface, and an R
state, where the cytoplasmic domain is unfolded and membrane detached. Previous studies have shown that
the PLN conformational equilibrium is crucial to SERCA regulation. Here, we used a combination of solution
and solid-state NMR to compare the structural topology and conformational dynamics of monomeric PLN
(PLNAFA) with that of the PLNR14del, a naturally occurring deletion mutant that is linked to the progression of di-
lated cardiomyopathy. We found that the behavior of the inhibitory transmembrane domain of PLNR14del is sim-
ilar to that of the native sequence. Conversely, the conformational dynamics of R14del both in micelles and lipid
membranes are enhanced. We conclude that the deletion of Arg14 in the cytoplasmic region weakens the inter-
actions with themembrane and shifts the conformational equilibrium of PLN toward the disordered R state. This
conformational transition is correlated with the loss-of-function character of this mutant and is corroborated by
SERCA's activity assays. These ﬁndings support our hypothesis that SERCA function is ﬁne-tuned by PLN confor-
mational dynamics and begin to explain the aberrant regulation of SERCA by the R14del mutant. This article is
part of a Special Issue entitled: NMR Spectroscopy for Atomistic Views of Biomembranes and Cell Surfaces.
Guest Editors: Lynette Cegelski and David P. Weliky.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Calcium transport in the heart muscle is orchestrated by several dif-
ferent membrane proteins. In particular, the uptake of Ca2+ ions into
the sarcoplasmic reticulum (SR) is governed by a membrane protein
complex between the sarco(endo)plasmic reticulum Ca2+-ATPase
(SERCA) and phospholamban (PLN) [1–3]. This complex is responsible
for about 70% of the Ca2+ transport into the SR in humans. Theof function;PKA,protein kinase
6AC41FC46A;PLNWT,wildtype
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Health (GM072701).
rch St. SE, Jackson Hall, 6-155,
el.: +1 612 625 0758; fax: +1paramount importance of the SERCA/PLN complex stems from its direct
involvement in the cardiac output [4]. Dysfunctions in Ca2+ handling by
this membrane protein complex lead to the progression of several car-
diomyopathies with eventual development of heart failure [5]. To
date, several different mutations of the pln gene have been sequenced
and identiﬁed in humans who develop hereditary cardiomyopathies.
Among those, a mutation in the pln promoter, a truncation resulting in
a PLNL39stop mutant, aberrant R9C, R9L, and R9H mutations, as well as
pln gene duplications, have been directly linked to either dilated or hy-
pertrophic cardiomyopathy [6–9]. Additionally, a recurring deletion of
arginine 14 (R14del) in the regulatory domain of PLNwasﬁrst observed
only in heterozygous patients suffering from dilated cardiomyopathy
(DCM), a disorder of the heart manifested as enlargement of the left
ventricle [8]. Subsequent genetic screening studies of a wider popula-
tion, broadened the impact of this PLN mutant, not only identifying
the Arg14 deletion in patients diagnosed with dilated cardiomyopathy,
but also in those with arrhythmogenic right ventricular cardiomyopa-
thy [10].
Powered by ATP, SERCA translocates two Ca2+ ions into the SR in ex-
change for three H3O+ ions. It is reversibly inhibited by PLN, a 52 amino
acid single-pass membrane protein [11]. PLN exists as a pinwheel-
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membrane domain II and more hydrophilic domain Ib crossing the
lipid membrane with a ~15–20° tilt angle [12–14]. The transmembrane
domains of the protomers are arranged in a left-handed coiled-coil of
approximately 40 Ǻ in length. In the ground state, the cytoplasmic, reg-
ulatory region (loop and domain Ia) is adsorbed on the membrane sur-
face. This interaction is stabilized by the energetically favorable contacts
between the aliphatic residues of the domain Ia helix with the hydro-
phobic core of the membrane, as well as the electrostatic interactions
of the polar residues with the lipid head groups and the bulk solvent.
Mutagenesis and biophysical data have lead to a regulatory model in
which de-oligomerized PLN forms a 1:1 inhibitory complex with the
ATPase [11,15]. Following phosphorylation at Ser16 by protein kinase
A (PKA), PLN inhibition is negated and Ca2+ ﬂux in the SR is augmented.
This model was recently conﬁrmed by three different crystal structures
obtained with PLN and its homologous analog sarcolipin (SLN) in com-
plex with SERCA [16–18]. The inhibitory domains of the two proteins
(i.e., the transmembrane domain II for PLN) bind in a hydrophobic
groove between TM2 and TM9 of the ATPase. However, the scarce
resolution of electron density for the cytoplasmic domain of PLN did
not enable the clariﬁcation of the molecular details of its regulatory
mechanism.
In the past years we have used NMR spectroscopy to determine PLN
structures free and bound to SERCA [13,19,20]. Based on our studies, we
proposed a regulatory model in which PLN conformational equilibrium
is central to SERCA regulation. We found that PLN exists in three main
states: a ground state (T state) with the cytoplasmic domain adsorbed
on the surface of the lipid membrane, an excited state (R state), where
the cytoplasmic domain is unfolded and membrane detached, and a
SERCA bound state (B state), where the transmembrane domain of
PLN is bound to SERCA and the extended domain Ia interacts with
SERCA's cytoplasmic domains [21–23]. Phosphorylation at Ser16 shifts
the equilibrium toward the B statewith a local structural rearrangement
[19]. The existence of the different PLN structural states is corroborated
bymutagenesis studies, demonstrating that it is possible to promote the
R and B states with concomitant relief of SERCA inhibition [24].
Here, we investigated how the alteration of the conserved amphi-
pathic motif via a naturally occurring amino acid deletion in the cyto-
plasmic domain affects PLN conformational equilibrium and its
regulation of SERCA. Challenges associated with studying membrane
proteins called for a combination of solution and solid-state NMR exper-
iments [25]. We found that the deletion of Arg14 slightly alters the
transmembrane domain of the protein, as well as induces a pronounced
shift of the conformational equilibrium of the cytoplasmic domain to-
ward the membrane-detached R state. Furthermore, we found that in
contrast with PLN, synthetic phosphorylation of PLNR14del does not
relieve inhibition of SERCA. This suggests that the PLNR14del mutant
functions as a constant inhibitor of SERCA, unresponsive to typical reg-
ulatorymechanisms likeβ-adrenergic stimulation. Analyzing these data
with the dynamic ruler we developed for site speciﬁc mutants of PLN,
our data begins to rationalize the loss-of-function nature of R14del
and how it inﬂuences not only Ca2+ transport in the SR but also the de-
velopment of cardiomyopathies for individuals carrying this mutation.
2. Material and methods
2.1. Protein production
Phospholambanwith a deletion of Arg14was produced from PLNAFA
by site-directedmutagenesis, usingQuikChange kit (Stratagene, La Jolla,
CA). Expression and puriﬁcation steps were identical to the host se-
quence [26]. Brieﬂy, the construct was expressed with R14del fused
with maltose binding protein via a tobacco etch virus protease cleavage
site. Fusion proteinwas puriﬁed by afﬁnity chromatography on amylose
resin, and upon cleavage — by high performance liquid chromatogra-
phy. To produce Ser16 phosphorylated R14del for the activity assays,we have employed microwave assisted solid phase peptide synthesis as
described previously, using Fmoc-Ser[PO(OBzl)] (Merck, Darmstadt,
Germany). Phosphoserinewas coupled at 50 °C; subsequent deprotection
steps were performed at room temperature and amino acids 1–15were
coupled at 50 °C to reduce the risk of dephosphorylation. SDS-PAGE of
Ser16-phosphorylated R14del is shown in Supplementary Fig. 1.
2.2. Nuclear magnetic resonance
Solution NMRwas performed as described previously. Phospholam-
banwas reconstituted in dodecylphosphocholine-d38 and the relaxation
measurements were performed at 600 MHz proton frequency on a
Varian spectrometer [27]. Separated local ﬁeld experiments were per-
formed on R14del reconstituted in DMPC:POPC 4:1 bicelles, doped
with 1% (mol) DMPE-PEG350 and 1% (mol) PE-DTPA to promote ytter-
bium ion chelation. Protein was reconstituted in long chained lipids,
followed by the addition of the capping lipid (1,2-dihexanoyl-sn-
glycero-3-phosphocholine; DHPC) [28]. The q-ratio (total long chained
lipid to short chained lipid) was 4.5. To promote the parallel orientation
of the bicelles YbCl3 was added to the ﬁnal concentration of 8 mM [29].
The 15N–1H SE-PISEMA experiment was performed on uniformly la-
beled 15N PLN at 700 MHz on a Varian spectrometer. Magic angle spin-
ning experiments were recorded on uniformly labeled 13C/15N PLN in
DMPC-d54. Multilamellar vesicles containing PLN were pelleted down
overnight at 250,000 g; the pellet was transferred into a Bruker 22 μl
rotor and additional buffer was added to ensure that the sample retains
hydration throughout the experiment. Refocused INEPT 13C–1H spectra
were recorded at 10 kHz spinning rate on a 700 MHz spectrometer.
2.3. SERCA ATPase assays
SERCA1a was extracted from rabbit skeletal muscle and puriﬁed
using afﬁnity chromatography using previously described methods
[30]. SERCA1a and PLN were co-reconstituted in 1,2-dioleoyl-sn-
glycero-3-phosphocholine: 1,2-dioleoyl-sn-phosphoethanolamine
(Avanti, Alabaster, AL) at a 4:1molar ratio in lipid vesicles as previously
described [31]. Molar ratios of 10:1 PLN:SERCA and 700:1 lipids:SERCA
were used. The Ca2+ dependence of SERCA's ATPase activity was mea-
sured spectrophotometrically with a Spectromax microplate reader
(Molecular Devices) as a function of NADH consumption using coupled
enzyme assays at 37 °C as previously described [32,33]. Solutions were
equilibrated at 37 °C before the experiment and reaction platewas incu-
bated at 37 °C for 20 min before reaction initiation. The initial rate of
ATPase activity (V) was measured as a function of calcium concentra-
tion and the data were ﬁt using a standard Hill equation:
V ¼ V max
1þ 10n pKCa−pCað Þ
where V is the initial rate of ATPase activity, Vmax is the maximal rate, n
is the Hill coefﬁcient, pCa is the log of the Ca2+ concentration, and pKCa
is the pCa value where V = Vmax / 2.
The assays were performed with three separate reconstitutions,
with triplicate measurements for each separate reconstitution.
3. Results
3.1. SERCA ATPase assays
Haghighi and coworkers found that PLNR14del acted as a partial loss-
of-function mutant in microsomal preparations [8]. In this study, we
measured the effect of the R14del mutant of PLN on SERCA activity for
both unphosphorylated and phosphorylated PLNR14del in reconstituted
lipid vesicles. We found that theΔpKCa for PLNR14del is 0.17, which indi-
cates a loss of inhibitory potencywith respect to PLNAFA (ΔpKCa= 0.26)
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and coworkers in HEK cells [8].
The deletion of Arg14 in the cytoplasmic domain of PLN disrupts the
R-R-X-S motif required for phosphorylation of Ser16 by PKA. Thus, it
was predicted and shown by Young and coworkers that phosphoryla-
tion of PLNR14del would be hindered. In this study, we used synthetic
phosphorylation methods to determine that even upon phosphoryla-
tion of PLNR14del, inhibition of SERCA is not relieved (Fig. 1, B), unlike
phosphorylation of PLNAFA at S16, which reverses inhibition. The pKCa
for PLNR14del with phosphoserine (pSer) at position 16 is virtually su-
perimposable with the pKCa of PLNR14del. This result implies that
PLNR14del would exert a constitutive inhibitory effect on SERCA even
upon PLNR14del phosphorylation by PKA, abolishing an important regu-
latory mechanism for the SERCA/PLN complex.
3.2. Structural dynamics of PLNR14del in micelles
Our solution and solid-state NMR studies have emphasized the poly-
morphic behavior of PLN cytoplasmic domain [19,34], which adapts its
structure to different binding partners or membrane surfaces [20,35].
The stretch of alternating hydrophobic and polar amino acids confers
an amphipathic and dynamic character to the ﬁrst 17 residues of PLN
(Supplementary Fig. 2); establishing the structural equilibriumbetween
the membrane-adsorbed helical T state and the solvent exposed, un-
folded R state. This conformational equilibrium plays a fundamental
role in Ca2+ homeostasis, since it regulates the extent of the ATPase in-
hibition and maintains SERCA activity within a physiological window.Fig. 1. ATP hydrolysis assay of SERCA alone (A and B: ﬁlled circles), in the presence of
PLNAFA (A and B: open circles) or R14del (red) in the non-phosphorylated state (A) or
pS16 modiﬁed (B). Lipid system is multilamellar vesicles of DOPC:DOPE 4:1 (mol:mol),
the lipid:SERCA:PLN molar ratio being 700:1:10. Error bars represent the standard devia-
tion of the three measurements (see also Material and methods section).Disproportionate inhibition (super-inhibition) or complete ablation of
PLN causes SERCA to function outside this window, leading to aberrant
regulation of Ca2+ ﬂux and progression to cardiomyopathy. Based on
the previously reported high-resolution structures of PLNAFA and
PLNWT, we predicted that the deletion of a polar residue would disrupt
the amphiphilic nature of the cytoplasmic domain, reducing the interac-
tions with the lipid membrane and promoting the unfolded, R state. To
test our hypothesis, we ﬁrst performed solution NMR spectroscopy to
determine the effects of R14 deletion on the monomeric form of
PLNR14del, which carries three mutations in the transmembrane domain
(C36A, C41F, and C46A) that deoligomerize the pentamer.
The [1H,15N]-HSQC spectrum of monomeric R14del reconstituted in
DPCmicelles exhibits excellent resolution of the resonances, with virtu-
ally nooverlapping residues. Even the transmembrane domain residues,
which are typically crowded due to the amino acid degeneracy and sim-
ilar chemical environment, are fully resolved for PLNR14del (Fig. 2, A). To
gain initial insights into the structural behavior of R14del, wemeasured
the chemical shift perturbations relative to PLNAFA under the identical
conditions (Fig. 2, B). The majority of the changes are localized near
the deletion site and propagate from the juxtamembrane domain Ib to
the transmembrane domain II, with Ser16 and Glu19 exhibiting the
largest perturbations. These effects resemble the case of S16 phosphor-
ylation, where the local chemical shift perturbations are associatedwith
the unfolding of the domain Ia helix and concomitant detachment of
this domain from themembrane, leading to an increase of the local ﬂex-
ibility [13]. To conﬁrm that the structural changes manifested by the
shift in the resonance frequencies correspond to changes in the confor-
mational dynamics, we measured T1, T2 and [1H,15N]-NOE for the back-
bone amide groups. Fig. 3 shows the dimensionless parameters used to
assess the extent of the mobility of the backbone atoms [36]. To placeFig. 2. HSQC spectrum of monomeric R14del in DPC-d38 micelles at a 450:1 detergent:
protein (mol:mol). Residue numbers are indicated. Chemical shift perturbation plot relative
to PLNAFA in DPC-d38 micelles is shown as a function of the residue number.
Fig. 3. Fast dynamics of R14delmeasured by solutionNMR relaxation experiments inDPC-
d38 micelles.
Fig. 4. SE-PISEMA spectra of PLNAFA (A) and PLNAFA R14del (B) in DMPC:POPC (4:1)/DHPC
bicelles (q = 4.5), aligned parallel to the magnetic ﬁeld. Long chained lipids to protein
ratio is 130:1 (mol:mol).
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ed for PLNAFA both in phosphorylated and non-phosphorylated states
[27,37]. The fast dynamics evaluated by the R1 × (1− NOE) parameter
showdrastic changes in the cytoplasmic domain,with themost affected
residues spanning positions 15–21. The increase in local motions of the
cytoplasmic domain is not as extensive as for pSer16 PLNAFA. The chang-
es in motions are localized around the deletion site and appear to level
off nearAla11. Since R14 deletion occurs toward the end of the cytoplas-
mic helix, it affects only one turn of domain Ia [38]. The remaining
stretch of residues is still sufﬁcient to form 2–3 turns of a helix, presum-
ably stabilized by aromatic and long chain aliphatic residues that anchor
this domain to themembrane [39]. Other relaxation parameters related
to the motion in the μs–ms timescale can be estimated from the prod-
ucts or the ratios of the transverse (R2) and longitudinal (R1) relaxation
rates. The R2/R1 ratios are used to assess the global correlation time and,
as for PLNAFA, they identify two distinct regions for the cytoplasmic and
transmembrane domains. The R2/R1 ratios for the transmembrane do-
main II are identical for both monomeric and pentameric PLN since
the correlation time is largely deﬁned by the tumbling of the bulky mi-
celle itself [40–42]. Conversely, the fast conformational dynamics of the
cytoplasmic domains resemble the values obtained for pSer16 PLNAFA
[43]. The R2 × R1 product for the cytoplasmic residues indicates the pres-
ence of low frequency motions near the phosphorylation site of pSer16
PLNAFA, which are absent in PLNR14del.
Overall, the dynamic behavior of R14del in micelles is intermediate
between the inhibitory PLNAFA and the non-inhibitory Ser16-
phosphorylated form. The R14del mutant has enhanced dynamic be-
havior near the deletion site, which we attribute to local helix unwind-
ing and detachment from the membrane. The effect is not as
pronounced as for pSer16 PLN, the non-inhibitory form of PLN; none-
theless, these seeminglyminor changes in the conformational dynamics
of R14del affect the inhibitory potency of PLN [24,44].
3.3. Topology of PLN in oriented lipid bilayers
We previously found that the structural coupling between the
membrane embedded and cytoplasmic domains is essential to PLN'sinhibitory function, and altering this coupling through site-speciﬁc mu-
tations, such as P21G, abolishes its inhibitory activity [24,38]. To under-
stand the effects of R14 deletion on the structural coupling between the
two regions of PLN, we analyzed its structural topology using oriented
solid-state NMR, reconstituting the protein in oriented lipid bicelles
[45]. Unlike in solution NMR, aligned solid-state NMR samples allow
one to measure anisotropic properties such as chemical shift (CS) and
dipolar couplings (DC) and deduce the topology of helical domains
with respect to the membrane normal [46,47]. To probe the CS and
DC, we used a sensitivity enhanced version of the polarization inversion
spin exchange at the magic angle (or PISEMA) experiment, a separated
local ﬁeld experiment that correlates anisotropic chemical shifts with
the dipolar couplings in oriented samples [45–47]. For the lipid bicelle,
we employed a mixture of DMPC/POPC/DHPC, a composition that pro-
motes the magnetic alignment at 25 °C. We used ytterbium ions to ori-
ent the bicelles with the lipid bilayer normal parallel to the applied
magnetic ﬁeld. The resonances of the membrane spanning domain of
PLNR14del are observed in same region of the corresponding SE-
PISEMA spectrum of the PLNAFA sequence (Fig. 4). The large span of
the 15N anisotropic chemical shifts and 15N–1H dipolar couplings indi-
cate that the helical axis is tilted by approximately 30–35° with respect
to the normal of the lipid bilayer. Previous studies from our group
showed that the tilt angle of PLNWT is dependent on the lipid bilayer
thickness as well as the choice of the alignment system — mechanical
or magnetic [13]. Similar behavior is observed for the monomeric spe-
cies, where the tilt angle in DMPC:POPC bicelles is some 10–15° lower
than the one in DOPC:DOPE glass slides. Although the tilt angle adopted
by PLNR14del is similar to that of PLNAFA, it is possible to observe a shift in
register of the resonance pattern, indicating a possible change in the az-
imuthal angle, although this qualitative assessment needs to be con-
ﬁrmed by site-speciﬁc assignments. Several resonances of the PISEMA
spectrum do not follow the pattern for the well-deﬁned helical trans-
membrane domain (Fig. 4, B). We detected an intense signal at
110 ppm region arising from the side chains of Asn and Gln residues
as well as several backbone signals with lower intensity, resonating in
the 115–125 ppm range. These latter residues must have high mobility,
as signals appearing in this area correspond to near isotropic motion.
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brane domain correspond to the region of PLN that is rigid and helical
(blue arc in Fig. 4, B). It does not form a continuous α-helix with the
rest of the membrane-spanning segment, as it would otherwise fall on
the same PISA wheel (red oval in Fig. 4, B). Based on the comparison
with PLNAFA, we tentatively assigned these resonances to the residues
located in the C-terminal part of domain Ib. This is in contrast with
PLNAFA, where there is a drastic reduction of signal intensity for domain
Ib starting at L28 (Fig. 4, A). We tentatively assign the weak signals of
PLNR14del near 150 ppm and 4 kHz to Q26 and N27 located at the
membrane–water interface.
The PISEMA spectrum of the R14del mutant does not show any sig-
nals corresponding to the cytoplasmic domain, which should resonate
at 70–80 ppm and 3–4 kHz. Solution NMR in micelles revealed an en-
hanced dynamic regime of the N-terminal residues for R14del. This
led us to investigate the dynamics in the native-like environment of
lipid bilayers [48] with an additional technique that is exclusively sensi-
tive toward residues that exhibit fastmotions, namelymagic angle spin-
ning (MAS) spectroscopy using a refocused INEPT transfer [49,50]. To
reduce the signals arising from the natural 13C in lipids, we used
DMPC deuterated at the acyl chains (DMPC-d54). The rINEPT spectra of
PLNAFA (Fig. 5, A–B) showprimarily the termini of the side chain groups,
with distinct spectral signatures of themethyl groups as well as the ion-
izable side chains. In the case of R14del (Fig. 5, C–D)we detected signif-
icantly more resonances for the cytoplasmic domainwith respect to the
corresponding spectrum of PLNAFA. The detected signals for Val, Leu, Ile,
and Lys include the methylene groups of the side chains, while for Ala,
Glu and Argwe observed correlations up to the backboneα-carbon. Ad-
ditionally, we detected distinct Cβ–Hβ and Cα–Hα signals for Thr whichFig. 5.Magic angle spinning spectra of PLN reconstituted inDMPC-d54 at 45:1 lipid:protein (mol:
(E–F). Protein is PLNAFA (A, B) or PLNAFA R14del (C-F).were absent in PLNAFA. The detection of signals for Thr 8 and 17 suggests
that the entire cytoplasmic domain (up to domain Ib) is more mobile
than PLNAFA. To probe solvent accessibility for R14del, we recorded
rINEPT with NOESY transfer scheme. This experiment enabled us to ob-
serve cross-peaks between the carbons of PLN and protons of water
(Fig. 5, E–F). Indeed, we observe multiple side chains of R14del that
are exposed to water. As expected, the ionizable moieties of Glu, Lys
and Arg are all solvent exposed, suggesting that they remain charged
in R14del. Additionally, we detected several aliphatic residues, namely
themethyl groups of Ala, Met, Val, Leu and Ile that all show correlations
with the water peak. Furthermore, the methylene group of Val and
backbone of Ala and Arg are also in contactwithwater, which reinforces
our solution NMR relaxation data and explains the lack of signals in the
PISEMA experiment for the cytoplasmic residues.3.4. Loss-of-function character of PLNR14del
To further look at the R14delmutation in contextwith other loss-of-
function (LOF) mutants, we performed analysis correlating the 1H–15N
heteronuclear NOE values of the loop and domain Ib to the change in
SERCA Ca2+ afﬁnity induced by the presence of the mutant (Fig. 6). As
previously reported, a plot of ΔpKCa versus ΔNOE yields a correlation
between the structural dynamics and function,what we deﬁne as a “dy-
namic index” [24,44]. We have previously hypothesized that the in-
creased dynamics of the cytoplasmic domain allows LOF PLN mutants
to more readily sample excited states, pushing the populations toward
the non-inhibitory B-state [19,20]. Inclusion of R14del in this structural
dynamics–function correlation shows that this mutant ﬁts the patternmol). Refocused INEPT (A–D)andNOESY-rINEPT, showing correlationwith thewater peak
Fig. 6. Activity-dynamics correlation of PLN mutants in relation to PLNAFA and PLNAFA
phosphorylated at Ser16 (pS16).
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loop domains.
4. Discussion
In PLNWT knockout mice, expression of PLNR14del is cardiotoxic, with
all animals carrying the R14del allele exhibiting an increased size of the
heart muscle and higher mortality rates [8]. Also, contractility measure-
ments carried out on isolated cardiomyocytes from R14del mice
matched those observed in the PLN-knockout line [8,51]. Inmicrosomal
preparations, PLNR14del demonstrates a loss-of-function character with
respect to PLNWT. However, co-expression of PLNWT and R14del results
in super-inhibition of SERCA, which was only partially reversed by pro-
tein kinase A phosphorylation. Based on these data, it has been pro-
posed that the pathological nature of R14del was due to SERCA super-
inhibition [8]. A possible explanation provided by these researchers
was that the arginine deletion destabilized the pentameric assembly
of PLN leading to de-oligomerization and increased inhibitory potency
toward SERCA [8,51]. This hypothesis is supported by immunostaining
data in microsomes as well as 32P radiography, which showed PLN
bands corresponding to lower molecular weight oligomers, although
the pentameric assembly of PLNR14del seems to be still present [8,51].
Phospholamban R14del has increased ﬂexibility of the cytoplasmic
domain and diminished ability to inhibit SERCA. Such features would
typically render a mutant a favorable candidate for improving cardiac
contractility in failing hearts, sharing similarities with the S16E, S16E–
T17E, and P21G mutants of PLN [44]. Based on these factors alone, one
would assume that R14del would not lead to cardiomyopathy; this im-
plies that the dysfunction induced by this mutation is rooted in other
regulatory mechanisms, such as its interactions with regulatory en-
zymes, including protein kinase A. The recent work from Young and
co-workers shows that phosphorylation of R14del by protein kinase A
is hindered [52]. This is likely due to the lack of a P-3 site necessary
for protein kinase A catalytic efﬁciency [53–55]. Additionally, it is not
possible to exclude that deletion of R14 would also cause disruption of
other protein–protein interactions that characterize PLN interactome,
such as A-kinase anchoring proteins (AKAPs), protein phosphatase
(PP1), or CamKII kinase. PLNR14del is a poor substrate for PKA since it
lacks the catalytic motif needed for phosphorylation. However, we
have shown here that even if a fraction of the PLNR14del population is
able to be phosphorylated by PKA, this will not reverse inhibition of
SERCA activity. Our result explains the partial reversal of inhibitionseen by Haghighi and co-workers when they co-expressed PLNWT
with PLNR14del. We saw no relief of inhibition upon phosphorylation of
Ser16 with the R14del mutant, indicating that Haghighi and co-
workers measured relief of PLNWT inhibition of SERCA, while PLNR14del
inhibition on SERCA persisted.
Solid-state NMR spectra of R14del PLNAFA indicate that its inhibitory
transmembrane domain mostly retains the topology of the host se-
quence, albeit we cannot exclude the possible change in the azimuthal
angle of the transmembrane helix. The regulatory segment of PLN, har-
boring the arginine deletion is more mobile and not observed through
cross-polarization, but can be readily detected in rINEPT spectra. Impor-
tantly, not only the side chains (which are intrinsically more mobile)
can be seen in R14del rINEPT, but several backbone signals are detected
as well. NOESY transfer between R14del and water illustrates that the
cytoplasmic domain is solvated, suggesting that the conformational
equilibrium of R14del is shifted toward the unfolded, membrane-
detached R-state. The dissociation of the cytoplasmic domain from the
membrane is likely a combination of several factors. First, the wild
type sequence is itself polymorphic, adopting several structural states.
Therefore, changes in the primary sequence may shift the structural
equilibrium toward a speciﬁc state.While several amphipathic peptides
are unstructured in water and fold in the presence of the lipid bilayer
[56], this is not the case for PLN's cytoplasmic domain. Second, elimina-
tion of the ionized residue can weaken electrostatic interactions of the
protein with the lipid headgroups [57]. Third, a deletion of a residue in
the amphipathic segment has an effect of changing the amino acid reg-
ister on the helical wheel, interspersing the hydrophobic and hydrophil-
ic side chains. Several studies have shown that suchmutations can alter
the structure and/or topology of the peptides [58]. Based on these con-
siderations, we anticipate that the naturally occurring PLNmutations at
Arg9 to a hydrophobic residue may have a similar effect, with the regu-
latory cytoplasmic domain of the R9X mutants exhibiting altered dy-
namics relative to the wild type.5. Conclusions
Using solution and solid-state NMRmethods, we analyzed the struc-
tural dynamics and topology of the R14del mutation in correlation with
SERCA ATPase assays. While R14del is related to the development of
cardiomyopathy, the structural and dynamic features of this mutant
correlate with the structure–dynamics–function relationship that we
previously identiﬁed for several loss-of-function PLN mutants that re-
lieve SERCA inhibition. These results reveal that in an isolated system,
removal of the Arg14 residue renders PLN a less potent inhibitor of
SERCA. Interestingly, phosphorylation of PLNR14del at Ser16 does
not relieve inhibition and mimics the functional behavior of pSer16
PLN. Considering that the increased dynamics observed by NMR
and the diminished SERCA inhibition would lead to an increase in
SERCA activity and possibly cardiac contractility, the deleterious
physiological consequences of the R14 deletion appear to be com-
prised of a variety of mechanisms, some of which are dependent on
proteins involved in the tight interplay that occurs during calcium
signaling. Because of the location of themutationwithin the recogni-
tion sequence of these enzymes, likely binding partners of PLN that
are directly affected by the deletion of Arg14 are protein kinase A
and protein phosphatase I. These proteins are central to maintain
phosphorylation levels and Ca2+ transport within the physiological
range.Note added in proof
After the submission of the revisedmanuscript, Hughes andMiddleton
also reported on the enhanced conformational dynamics of PLNR14del
(PLOS One, e106746).
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